Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Novo moves into amyloidosis not long after Intellia made a splash here.
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.